ClinicalTrials.gg
Active, not recruitingNCT07816731SM-VR-DEMENTIAUpdated Oct 6, 2026

EFFECT OF FACE-TO-FACE AND VIRTUAL REALITY-BASED SALUTOGENESIS NURSING CARE IN PATIENTS WITH DEMENTIA

An interventional study of Face-to-Face Salutogenesis Model-Based Nursing Care and Virtual Reality-Supported Salutogenesis Model-Based Nursing Care in Dementia, sponsored by TC Erciyes University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by TC Erciyes University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2026, registered Sep 2026).
Updated Oct 6, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Dementia with a site in Turkey — 6 open to participants now, 10 under way, none of them phase 3. Dementia · Turkey.

Planned enrollment
9th of 32
73 · median 56
Started
2026
with 2 others
No phase
29 of 40
2 open now
Registered
40th of 40
by date

Among the 40 studies in Dementia with a site in Turkey, this one is the 9th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2026, is one of 29 with no phase, and was the 40th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

6 of the 40 studies in Dementia with a site in Turkey are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Dementia with a site in Turkey, or all of them as a file.
02

Study summary

The purpose of this clinical study is to examine the effects of nursing care based on the Salutogenesis Model on the sense of coherence (meaningfulness, comprehensibility, and manageability) and quality of life of people living with dementia. The study will also evaluate whether delivering this nursing care face-to-face or through virtual reality leads to similar or different benefits, and whether these benefits are maintained over time.

The main questions this study aims to answer are:

Does face-to-face nursing care based on the Salutogenesis Model help people living with dementia strengthen their sense of coherence, cope better with daily life, and improve their quality of life? Does delivering the same nursing care using virtual reality lead to similar or different effects on sense of coherence and quality of life compared to face-to-face care? Do the positive effects of this nursing care continue after the intervention has ended? Researchers will compare three groups to answer these questions: a group receiving face-to-face nursing care based on the Salutogenesis Model, a group receiving the same nursing care using virtual reality, and a control group receiving usual care.

Participants will take part in the study over a period of several months. During the study, participants will be asked to:

Take part in nursing care sessions once a week for eight weeks Complete questionnaires that assess sense of coherence and quality of life Complete these questionnaires at the start of the study, after the eight-week nursing care program is completed (mid-term follow-up), and approximately three months after the interventions have ended (final follow-up) These assessments aim to evaluate both the short-term effects of the nursing care and whether these effects are sustained over the longer term.

The results of this study are expected to contribute to the development of more supportive and innovative nursing care approaches for people living with dementia and to provide evidence on the use of virtual reality as a supportive tool in nursing care.

Read the detailed description

DETAILED DESCRIPTION

This study is a randomized controlled experimental trial designed to evaluate the effects of nursing care based on the Salutogenesis Model on sense of coherence and quality of life in individuals living with mild to moderate dementia. The study compares the effectiveness of the same nursing care delivered through two different methods-face-to-face and via virtual reality (VR) headsets-against usual care.

The Salutogenesis Model focuses on individuals' capacity to understand their life situations, manage daily challenges, and find meaning in their experiences. The central concept of the model is sense of coherence, which consists of three components: comprehensibility, manageability, and meaningfulness. This study applies the Salutogenesis Model as a holistic nursing framework to support people living with dementia by strengthening these components despite cognitive decline.

Study Design and Setting The study will be conducted in Niğde Bor district, Türkiye, and coordinated through Bor State Hospital. All assessments and interventions will be carried out in participants' home environments to increase comfort, reduce barriers to participation, and reflect real-life conditions.

Participants with mild to moderate dementia will be randomly assigned to one of three groups:

Intervention Group 1 (MG1): Receives face-to-face nursing care based on the Salutogenesis Model Intervention Group 2 (MG2): Receives the same nursing care supported by virtual reality headsets Control Group: Receives usual care without additional structured nursing intervention Randomization will be performed using a computer-based simple randomization method by an independent researcher to minimize allocation bias.

Intervention Procedures Both intervention groups will receive an eight-week nursing care program based on the Salutogenesis Model. Sessions will be conducted once per week and will last approximately 40-60 minutes.

The content of the nursing care program is identical for both intervention groups and is structured to support:

Meaningfulness: through life review, reminiscence activities, meaningful memories, music, and personalized activities Comprehensibility: through structured routines, clear explanations, environmental organization, and supportive communication Manageability: through problem-solving strategies, daily activity planning, medication routines, and strengthening personal and social resources

In the VR-supported group, selected components of the intervention (such as reminiscence activities, meaningful environments, music, and visual stimuli) will be delivered using VR headsets, allowing participants to experience these elements in an immersive digital environment. The face-to-face group will receive the same content using traditional, in-person methods without VR.

Data Collection and Follow-Up

Outcome measures will be collected at three time points:

Baseline assessment (before intervention) Post-intervention assessment (after the eight-week nursing care program) Follow-up assessment approximately three months after the intervention ends These follow-up assessments are designed to evaluate both short-term effects and the sustainability of the intervention outcomes over time.

Primary outcomes include changes in sense of coherence (comprehensibility, manageability, and meaningfulness) and quality of life. Data will be collected using validated assessment tools administered through face-to-face interviews.

Significance By comparing face-to-face and VR-supported delivery of Salutogenesis Model-based nursing care, this study aims to provide evidence on whether digital health technologies such as virtual reality can be used as effective and supportive tools in dementia nursing care. The findings are expected to contribute to the development of holistic, innovative, and sustainable nursing interventions that enhance quality of life and sense of coherence in people living with dementia.

03

Conditions studied

  • Dementia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -Individuals aged 18 years and older.
  • Individuals who are able to read and write.
  • Individuals with a Standardized Mini-Mental Test (SMMT) score between 11 and 23, indicating mild to moderate dementia.
  • Individuals without severe speech or language impairments that would limit communication.
  • Individuals with non-progressive or clinically stable dementia, defined as cognitive symptoms that do not show marked deterioration over time.
  • Individuals who have provided written , or whose legal representative has provided written informed consent.
  • Individuals who are able to participate in the intervention sessions using virtual reality headsets independently or with the support of a caregiver.

Exclusion criteria

Exclusion Criteria:

  • Inability to complete assessments due to severe psychotic symptoms (e.g., hallucinations, paranoid thoughts) or uncontrolled behavioral symptoms such as aggression or severe agitation.
  • Presence of progressive neurological diseases that impair motor and cognitive functions, such as Parkinson's disease or Huntington's disease.
  • A Standardized Mini-Mental Test (SMMT) score below 10.
  • Being older than 80 years of age.
  • Absence of a caregiver.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
73 participants (estimated)

Study arms

  • Experimental
    Face-to-Face Salutogenesis Model-Based Nursing Care

    Participants in this arm will receive face-to-face nursing care based on the Salutogenesis Model. The intervention will be delivered once a week for eight weeks, with each session lasting approximately 40-60 minutes. The nursing care will be structured to strengthen sense of coherence (meaningfulness, comprehensibility, and manageability) and to improve quality of life.

    Behavioral: Face-to-Face Salutogenesis Model-Based Nursing Care

  • Experimental
    Virtual Reality-Supported Salutogenesis Model-Based Nursing Care

    Participants in this arm will receive Salutogenesis Model-based nursing care supported by virtual reality headsets. The content of the intervention will be the same as the face-to-face nursing care and will be delivered once a week for eight weeks, with each session lasting approximately 40-60 minutes. The nursing care will aim to strengthen sense of coherence and improve quality of life, while virtual reality will be used as a supportive tool for delivering selected components of the intervention.

    Behavioral: Virtual Reality-Supported Salutogenesis Model-Based Nursing Care

  • No intervention
    Usual Care (Control Group)

    Participants in this arm will continue to receive usual care during the study period and will not receive any additional structured nursing intervention related to the study.

Interventions

  • BehavioralFace-to-Face Salutogenesis Model-Based Nursing Care

    Nursing care based on the Salutogenesis Model delivered face-to-face once a week for eight weeks, with each session lasting approximately 40-60 minutes. The intervention focuses on strengthening sense of coherence by supporting meaningfulness, comprehensibility, and manageability, and aims to improve participants' quality of life through structured, person-centered nursing care.

  • BehavioralVirtual Reality-Supported Salutogenesis Model-Based Nursing Care

    Nursing care based on the Salutogenesis Model will be delivered using virtual reality headsets. The intervention will be provided once a week for eight weeks, with each session lasting approximately 40-60 minutes. The content of the intervention will be the same as that used in the face-to-face nursing care and will aim to strengthen sense of coherence and improve quality of life. Virtual reality headsets will be used as a supportive tool to deliver selected components of the nursing care in an immersive digital environment.

06

What researchers measure

Primary outcomes

  1. Sense of Coherence

    Sense of coherence will be assessed using the Sense of Coherence Scale (SOC-13), which evaluates the components of meaningfulness, comprehensibility, and manageability.

    Time frame: Baseline, after 8 weeks (post-intervention), and 3 months after the intervention

Secondary outcomes

  1. Quality of Life (WHOQOL-BREF)

    Quality of life will be assessed using the World Health Organization Quality of Life Scale (WHOQOL-BREF).

    Time frame: Baseline, after 8 weeks (post-intervention), and 3 months after the intervention

07

Study locations

1 site
  • Niğde/Bor
    Niğde, Bor, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to ethical considerations, the sensitive nature of the study population, and privacy concerns.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 7 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 14, 2026
StartActual
May 15, 2026
Primary completionEst.
Dec 15, 2026was Sep 2026
CompletionEst.
Dec 15, 2026was Sep 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Primary completion
Sep 15, 2026→Dec 15, 2026
Oct 6, 2026
Study completion
Sep 15, 2026→Dec 15, 2026
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 15, 2026→Dec 15, 2026
    Study completion Sep 15, 2026→Dec 15, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07816731
Responsible party
MERVE EKİN KILIÇASLAN (PhD Candidate, TC Erciyes University) — Principal investigator
First posted
Sep 14, 2026
Start date
May 15, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

HANDAN ZİNCİR, PhD
study director · Erciyes University, Faculty of Health Sciences, Department of Public Health Nursing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion